Boehringer Ingelheim China has partnered with ChromX Health, a Chinese high-tech company, to advance research on interstitial lung diseases (ILD). The collaboration aims to discover innovative solutions for early diagnosis and intervention of ILD, a group of disorders that can cause lung tissue scarring and ultimately lead to breathing difficulties and death if not treated promptly.
ILD is a complex disease with intricate contributing factors, and its early symptoms can be challenging to detect. To address these issues, Boehringer Ingelheim plans to collaborate with leading medical device companies, high-tech startups, and patient organizations in order to develop a patient-centered ecosystem for the comprehensive management of ILD patients.
This strategic cooperation between Boehringer Ingelheim China and ChromX Health follows the German company’s previous initiatives in building the ILD ecosystem. In May, Boehringer Ingelheim signed a cooperation agreement with Omron Healthcare China to further this endeavor.
During the recent sixth China International Import Expo in Shanghai, the signing ceremony for the partnership took place. Chen Xingrong, the general manager of human pharma at Boehringer Ingelheim Great China, shared that the ILD ecosystem’s vision is to provide one-stop solutions encompassing disease education, early screening, diagnosis, precision treatment, and disease management.
ChromX Health’s founder and CEO, Wang Junqi, expressed their excitement about expanding the company’s product research and development scope through this collaboration. ChromX Health aims to leverage advanced technologies, including artificial intelligence, to detect ILD patients and high-risk groups at an early stage. Wang envisions that standard treatment and disease management following early detection will become more feasible through their efforts.
Currently, ChromX Health is expediting the industrial manufacturing and commercialization of microminiature volatile organic compounds-based breath analysis devices. These devices can analyze biomarkers in breathomics, enabling disease screening, diagnosis, and precision medicine. The company plans to deploy these devices in both hospital and residential settings.
At the CIIE, Boehringer Ingelheim also showcased a new drug candidate undergoing Phase-3 clinical trials for the treatment of idiopathic pulmonary fibrosis, a rare and chronic lung disease.
As Boehringer Ingelheim China and ChromX Health join forces, their collaborative research on ILD aims to improve early diagnosis and intervention strategies. By leveraging cutting-edge technologies and forming partnerships with various stakeholders, they strive to offer comprehensive disease management solutions for ILD patients.
